Abstract
Objectives Evaluate the role of placenta growth factor (PlGF) as a predictor of preeclampsia (PE). Methods Systematic review on Pubmed (february/2014) with descriptor: “(placenta growth factor OR plgf) AND pre-eclampsia/diagnosis”’. A total of 126 articles were found. Items with more than three years of publication, systematic reviews, not related to the topic after reading the abstract and unavailability of the article were excluded. Among the papers which were read in full, three were excluded because they did not use as a predictive factor PlGF, totaling 19 items for the final sample. Results Due to the heterogeneity of the articles found, four groups were defined sorted into 4 groups: Group 1 PlGF isolated Fifteen studies were conducted as a single measure of PlGF and found a decrease in patients with PE; Ten in the first half of pregnancy; five found with lower values when PE early; four found with severe lower PE values Group 2 Relation sFlt-1/PlGF Six studies determined the relationship sFlt-1/PlGF and had an increase in pregnant women with PE values in the second quarter Group 3 Combination of PlGF Doppler velocimetry of uterine arteries Of the eight articles that combined biochemical to biophysical methods, five showed improvement in sensitivity and specificity with the combination, four in the first quarter Group 4 Combination of several biomarkers Three studies investigated various biomarkers, two achieved combination of markers. While Myatt et al. (2012) found increased diagnostic capacity with the association, Myers et al. (2013) did not obtain the same result combining several biomarkers Conclusions It is suggested that PlGF is reduced in PE, alternating the values in the first half of pregnancy, especially early/severe PE. The sFlt-1/PlGF ratio is better in the second trimester of gestation (late when compared to isolated PlGF). Diagnostic ability of PlGF can be extended by associating other methods, especially biophysical. Standardized studies are needed, homogenizing the collection time, cut off values and a way of presentation of the results for the comparison be clear. Disclosures G. Calestini: None. B. Reis: None. D. Labre: None. F. Fuentes: None. F. Sousa: None. L. Wenzel: None. P. Coelho: None. W. Chanwangyen: None. S. Prieto: None. D. Prieto: None. U. Markert: None. N. Sass: None.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.